New early embryo models offer hope for research on miscarriages, birth defects
Issued on:
17/03/2021 - 18:15 LLUIS GENE AFP/File
Tokyo (AFP)
Scientists have generated early-stage human embryo models that could help shed light on the black box of initial human development stages and improve research on pregnancy loss and birth defects.
Two separate teams found different ways to produce versions of a blastocyst the stage of development around five days after a sperm fertilises an egg potentially opening the door for a huge expansion of research.
The scientists make clear that the models differ from human blastocysts and are not capable of developing into embryos. But their work comes as new ethical guidelines on such research are being drafted and could spark fresh debate.
New early embryo models offer hope for research on miscarriages, birth defects yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
February 9, 2021
Priscilla Page
The University of Michigan department of theater and drama, and departmental student-faculty culturally conscious casting committee will host a roundtable discussion on culturally conscious casting and theater, with a panel of experts in the field on Friday, Feb. 12, at noon.
The roundtable is inspired by the book “Casting a Movement: The Welcome Table Initiative.”
Panelists include:
Daniel Banks, co-editor of “Casting a Movement” and co-director of DNAWORKS, an arts and service organization dedicated to using the arts as a catalyst for dialogue and healing.
Justin Emeka, director and associate professor of theater and Africana Studies at Oberlin College, and contributor to Casting a Movement.
Nanotech Jumps Blood-Brain Barrier To Kill Cancer in Mice
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research shows.
The study is the first to demonstrate an intravenous medication that can cross the blood-brain barrier.
I’ve worked in this field for more than 10 years and have not seen anything like this.
The discovery could one day allow new clinical therapies for treating glioblastoma, the most common and aggressive form of brain cancer in adults, and one whose incidence is rising in many countries. Today’s median survival for patients with glioblastoma is around 18 months; the average 5-year survival rate is below 5%.